Myopia progression is safely and effectively reduced by topical administration of a storage-stable low-dose formulation in which atropine is present at a concentration of 0.01%. Unexpectedly, such formulation was proven more effective to reduce myopia progression as compared to an otherwise identical formulation containing 0.02% atropine. For example, formulations with an atropine concentration of about 0.01% slowed down myopia progression as compared to subjects not receiving treatment.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
A sterile multi-dose ophthalmic consumer product, and especially a multi-dose low-concentration atropine eye drop container is disclosed having desirable atropine stability, low loss of viscosity, and low levels of total impurities leached from the container even after extended storage in the container.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present disclosure is directed to novel ophthalmic formulations comprising a gabapentinoid and methods for treating corneal pain using said formulations.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
Myopia progression is safely and effectively reduced by topical administration of a storage-stable low-dose formulation in which atropine is present at a concentration of 0.01%. Unexpectedly, such formulation was proven more effective to reduce myopia progression as compared to an otherwise identical formulation containing 0.02% atropine. For example, formulations with an atropine concentration of about 0.01% slowed down myopia progression as compared to subjects not receiving treatment.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
Ophthalmic formulations for treatment of night vision disturbance syndrome (NVD) are presented and preferably comprise brimonidine, rivastigmine, and/or galantamine at very low concentrations. Such formulations unexpectedly provided acute and transient therapeutic effect to alleviate one or more symptoms associated with NVD.
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 9/00 - Medicinal preparations characterised by special physical form
A topical ophthalmological formulation comprises carbachol at a low concentration that effects reduction in pupil diameter over time when repeatedly administered over at least a week. Such formulations are particularly beneficial where carbachol is the sole active agent in the treatment of presbyopia and night vision disturbance. Such and other formulations may also comprise modified carbachol exhibiting improved delivery to the pupillary muscle and will (further) beneficially reduce the required quantity of active agent while still producing a desired pupil size for a predetermined period of time. Moreover, such compositions may not require combination with a penetration enhancer, such as benzalkonium chloride, and will as such be better tolerated.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A sterile multi-dose ophthalmic consumer product, and especially a multi-dose low- concentration atropine eye drop container is disclosed having desirable atropine stability, low loss of viscosity, and low levels of total impurities leached from the container even after extended storage in the container.
A sterile multi-dose ophthalmic consumer product, and especially a multi-dose low- concentration atropine eye drop container is disclosed having desirable atropine stability, low loss of viscosity, and low levels of total impurities leached from the container even after extended storage in the container.
The present disclosure is directed to novel ophthalmic formulations comprising a gabapentinoid and methods for treating corneal pain using said formulations.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61P 25/04 - Centrally acting analgesics, e.g. opioids
Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time.
Ophthalmic formulations for treatment of night vision disturbance syndrome (NVD) are presented and preferably comprise brimonidine, rivastigmine, and/or galantamine at very low concentrations. Such formulations unexpectedly provided acute and transient therapeutic effect to alleviate one or more symptoms associated with NVD.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time.
Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
